According to Galapagos NV's latest financial reports the company's current revenue (TTM) is $0.25 B. In 2022 the company made a revenue of $0.53 B a decrease over the years 2021 revenue that were of $0.56 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.25 B | -52.3% |
2022 | $0.53 B | -5.64% |
2021 | $0.56 B | 3.57% |
2020 | $0.54 B | -41.58% |
2019 | $0.93 B | 176.72% |
2018 | $0.33 B | 130.42% |
2017 | $0.14 B | 4.57% |
2016 | $0.13 B | 220.09% |
2015 | $43.63 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 36,576.83% | ๐บ๐ธ USA |
Abbott Laboratories ABT | $40.10 B | 15,714.23% | ๐บ๐ธ USA |
AbbVie ABBV | $54.31 B | 21,316.57% | ๐บ๐ธ USA |
Sanofi SNY | $50.35 B | 19,755.97% | ๐ซ๐ท France |
Merck MRK | $60.11 B | 23,601.82% | ๐บ๐ธ USA |
AstraZeneca AZN | $45.81 B | 17,962.42% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $37.84 B | 14,823.17% | ๐ฌ๐ง UK |
Fortress Biotech
FBIO | $84.51 M | -66.68% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $15.84 B | 6,147.78% | ๐ฎ๐ฑ Israel |